Learn More
Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, ["l'In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic(More)
  • 1